Shasqi, Inc.

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company using in-vivo click chemistry to enable pre-targeting for ADCs and radioisotopes, today announced that Founder and CEO, José M. Mejía Oneto, MD, PhD, and VP of Research, Travis Biechele, PhD will both be presenting sessions at the 15th World ADC San Diego conference taking place in San Diego, between November 4-7th. Continue Reading Shasqi will also be presenting posters at the World ADC conference, as well as at the Society for the Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, between November 8-10th. Shasqi announces six presentations across two leading scientific conferences: World ADC in San Diego and SITC in Houston Post this The presentations and posters will share data from Shasqi's novel Click Activated Protodrugs Against Cancer (CAPAC®) technology, a pre-targeting approach using in-vivo click chemistry to enable preferential drug exposure in tumors versus normal tissues. This can be used to improve the therapeutic index of potent cytotoxic drugs or radioisotopes. "99% of the ADC dose is catabolically eliminated in normal tissues leading to active payload exposure and toxicity. I am eager to discuss what we can do as a field to reduce some of the target-independent toxicities seen with the ADC platform. Shasqi's pre-targeting approach is a potential solution to reduce payload exposure and toxicity to normal cells that applies to any payload including those from ADCs or targeted radiopharma approaches. I am excited to share data from our platform at World ADC," said VP of Research, Travis Biechele, PhD. Shasqi is seeking to establish new and advance existing conversations with partners around the applications of their CAPAC pre-targeting technology at both World ADC and SITC. Details on each of the sessions can be found below. World ADC speaking session - November 5th at 10:30am PDT Presenter: Travis Biechele, PhD. 5th Toxicity Day track Title: Understanding the drivers of target independent toxicities associated with ADCs and solutions to overcome them World ADC speaking session - November 6th at 12:45pm PDT Presenter: José M. Mejía Oneto, MD, PhD. Discovery Chemistry track Title: Click chemistry enabled pre-targeting as a solution to target-independent ADC toxicities World ADC Poster session - November 5th at 6:30pm PDT Poster 1 title: Pre-targeting with in vivo click chemistry enables preferential drug exposure in tumors versus normal tissues Poster 2 title: CEACAM5 is an ideal target for click chemistry enabled pre-targeting SITC 39th Annual Meeting - November 9th at 9:00am CDT Poster title: Doxorubicin-based click chemistry therapeutic activates potent cytotoxic immune responses in advanced sarcoma patients in a Phase 1/2a clinical trial Poster Number: 624 Poster title: Attenuated MMAE therapeutic activated by click chemistry at the tumor evokes potent immune responses Poster Number: 1278 About Shasqi and CAPAC® Shasqi's Click Activated Protodrugs Against Cancer (CAPAC®) technology is a pre-targeting approach using in-vivo click chemistry to enable preferential drug exposure in tumors versus normal tissues. The approach comprises of 1) a clickable binder, and 2) a clickable payload ('protodrug'). When reunited at the tumor using click chemistry, these components lead to maximal active therapeutic payload at the tumor. CAPAC is designed to expand the scope of potential targets and widen the therapeutic window of antibody drug conjugates (ADCs) and targeted radiopharma approaches. For more information, please visit and follow Shasqi on LinkedIn. SOURCE Shasqi, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN FRANCISCO, April 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024. The posters will describe data generated with Shasqi's CAPAC® (Click Activated Protodrugs Against Cancer) approach. CAPAC uses 2022 Nobel Prize winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure. This approach overcomes many limitations of antibody-drug conjugates (ADCs). "We are looking forward to sharing new data from the Shasqi pipeline at AACR," said Shasqi Vice President of Research, Travis Biechele, Ph.D. "It is exciting to see data showing that we can effectively activate cancer drugs at the tumor using antigen-bound activators, resulting in sustained tumor regression." Shasqi is advancing a pipeline of assets based on validated targets and payloads. The posters presented at the AACR meeting will show preclinical efficacy and safety data for assets targeting HER2, TROP2, and NECTIN-4, each paired with either an MMAE or exatecan payload. Presentations Abstracts are available and can be viewed on the AACR website. Monday, April 8 between 9 AM - 12:30 PM PST Click chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agent Lead Author: George Coricor, Ph.D. Poster Section 28, Poster Board: 13 Wednesday, April 10 between 9 AM - 12:30 PM PST Tumor targeted activation of an attenuated exatecan protodrug through Click Chemistry demonstrates efficacy in murine tumor studies Lead Author: Sangeetha Srinivasan, Ph.D. Poster Section 26, Poster Board: 1 A click chemistry-based HER2 targeting agent activates a decoupled MMAE payload making it highly differentiated in efficacy and safety than ADCs Lead Author: Sangeetha Srinivasan, Ph.D. Poster Section 26, Poster Board: 2 Nectin-4 targeted therapy with MMAE protodrug results in anti-tumor efficacy mediated by click chemistry Lead Author: George Coricor, Ph.D. Poster Section 26, Poster Board: 3 Improving anti-tumor efficacy by modulating a separate HER2 activator and an MMAE payload and reuniting both through click chemistry Lead Author: Stefanie Wagner Poster Section 26, Poster Board: 4 About Shasqi and CAPAC® Shasqi's unique CAPAC® (Click Activated Protodrugs Against Cancer) platform uses Nobel Prize winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the site of the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure. CAPAC builds on the advances achieved by antibody-drug conjugates (ADCs), changing what's possible with antigen targeted drug activation. Shasqi has developed an expansive and diverse library of antigen targeting activators and cancer therapeutic protodrugs. These two components are decoupled from each other and united at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans. Shasqi is advancing the development of new tumor targeting activators and protodrugs on an ongoing basis and is in active collaboration with partners in the biopharmaceutical industry to expand the CAPAC library of antigen targeting activators and protodrugs. For more information, please visit: and follow Shasqi on LinkedIn.

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 14th Annual World ADC Conference in London, United Kingdom on Tuesday March 12th at 11:00am GMT. The session titled "CAPAC: A Modular Platform for Tumor-Targeted Drug Activation Using Click Chemistry In Vivo" will be part of the "Supercharging ADC Efficacy & Conquering Toxicity Through Transformative Emerging Conjugation Technologies" track as part of the 2nd Generation Conjugates Day. "We are honored to be an invited speaker at the 2nd Next-Generation Conjugation Day during World ADC Europe—an event synonymous with innovation." said Dr. Mejía Oneto. "We're excited to share more about our technology and present new data demonstrating how our unique approach has the potential to meaningfully increase the therapeutic index of cancer drugs." As part of the session, Shasqi will share background on its novel Click Activated Protodrugs Against Cancer (CAPAC®) platform, which leverages click chemistry for tumor-targeted drug activation. Shasqi will also share clinical proof-of-concept data and unveil preclinical data from the pipeline, showcasing the ability to use antibody fragments to activate high potency payloads at the tumor. Shasqi has developed a novel approach to activating drugs at the tumor. First, an antigen targeting activator is infused, which binds to the tumor. Then, an inert version of a cancer therapeutic, called a protodrug, is infused. The protodrug finds the activator at the tumor and the active drug is released via a click chemistry reaction. Separation of payload from tumor targeting confers several advantages over antibody-drug conjugates (ADCs) including selective activation at the tumor and the ability to optimize the ratio of each component throughout development, including in the clinic. Together, this allows the therapeutic index of cancer drugs to be maximized. About Shasqi and CAPAC® Shasqi's unique CAPAC® (Click Activated Protodrugs Against Cancer) platform uses Nobel Prize winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the site of the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure. CAPAC builds on the advances achieved by antibody-drug conjugates (ADCs), changing what's possible with antigen targeted drug activation. Shasqi has developed an expansive and diverse library of antigen targeting activators and cancer therapeutic protodrugs. These two components are decoupled from each other and united at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans. Shasqi is advancing the development of new tumor targeting activators and protodrugs on an ongoing basis and is in active collaboration with partners in the biopharmaceutical industry to expand the CAPAC library of antigen targeting activators and protodrugs. For more information, please visit: and follow Shasqi on LinkedIn. SOURCE Shasqi, Inc.